Viatris Inc. (VTRS)

Viatris Inc. manufactures and sells generic drugs, biosimilar medications, and branded specialty pharmaceuticals across more than 165 countries. The company was formed in 2020 through the merger of Mylan N.V. (a leading generic drugmaker) and Upjohn, the spin-off of Pfizer’s older, off-patent pharmaceutical business. Viatris is headquartered in Pittsburgh, Pennsylvania, and operates one of the world’s largest portfolios of generic and biosimilar drugs — a business model built on delivering affordable medications to patients and health systems worldwide, often at prices far below the originator drugs they replace.

The generic and biosimilar playbook

A generic drug is a medication chemically identical to an off-patent brand-name drug, made by a different manufacturer. Once a patent expires — typically 20 years from filing — rival companies can legally manufacture and sell the same molecule at a fraction of the original price. Viatris profits by being exceptionally good at this: identifying expiring patents, navigating regulatory approval processes, manufacturing at low cost, and distributing globally.

A biosimilar is a more recent variant on the same principle. Biosimilar drugs are copies of expensive biologic drugs (medications made from living cells or proteins) whose patents have expired. Because biologics are far more complex than small-molecule chemicals, biosimilars take longer and cost more to develop and approve than generics. But the economics are similar: the first biosimilar into a market can capture substantial share from the originator at a much lower price, and competitors follow.

Viatris’s portfolio spans both worlds. It manufactures thousands of generic pills, injectables, and topicals — from antibiotics and diabetes treatments to cardiovascular drugs and pain relievers. It also operates a growing biosimilar franchise, which includes copies of high-value medications that patients rely on for cancer, autoimmune disease, and other serious conditions.

Why did Mylan and Upjohn merge?

The deal reflected a reordering of the global pharmaceutical industry. Mylan had spent the 2000s and 2010s pursuing aggressive growth through acquisition — buying hundreds of generic drug products and businesses across the United States, Europe, and emerging markets. It had become a powerhouse in generics but faced a ceiling: consolidation in the pharmacy benefits and insurance industry meant buyers (hospitals, health insurers) had more negotiating leverage, pushing prices down.

Upjohn was a drag on Pfizer. Pfizer, a research-driven maker of blockbuster drugs, inherited Upjohn in the 2009 Wyeth merger and spent years deciding what to do with the older, non-innovative part of the portfolio. By 2020, Pfizer’s leadership chose to spin out Upjohn and merge it with Mylan, creating a pure-play generic and off-patent pharmaceutical company with scale, scope, and the cash generation to fund biosimilar development.

The logic: a $15 billion company fighting on price alone would struggle. A $20+ billion company with diverse geographies, a massive generic portfolio, integrated manufacturing, and biosimilar ambitions could compete better globally and achieve operating leverage.

How Viatris makes money

Viatris’s revenue comes from three main buckets. Developed Markets — the United States, Europe, Canada, Japan, and other wealthy countries — is the largest, driven by massive volumes of generics dispensed through pharmacies and hospital systems. Prices are low (a month’s supply of a generic might cost a few dollars) but volume is enormous.

Emerging Markets is growing faster. In India, China, Brazil, Mexico, and dozens of other middle- and lower-income countries, Viatris markets branded and generic products under the Mylan, Upjohn, and other local labels. Prices are lower than in developed markets but often higher than in developed markets per unit, and the patient population is much larger. This segment benefits from rising healthcare spending and improving access to medicines as these economies develop.

Specialty Therapeutics — biosimilars, injectables for oncology and specialty conditions — carries higher prices and margins than commodity generics. It is smaller today but is intended to be a growth driver as the company invests in development.

The recurring element is prescription refills — once a patient is on a generic medication, they need that same refill month after month or year after year. This is not a blockbuster discovery business; it is a volume, reliability, and cost-management business.

The manufacturing and supply-chain edge

One of Viatris’s inherited strengths is a global network of manufacturing plants and active pharmaceutical ingredient (API) production. The company makes not just the finished pills and injections but also the raw ingredients that go into them. This vertical integration lets Viatris control costs and quality in a way that competitors relying entirely on outsourced ingredient suppliers cannot.

That said, pharmaceutical manufacturing is geographically concentrated — a lot of raw materials and intermediates come from India and China — so Viatris remains exposed to the same supply-chain risks as rivals. Recent years have seen drug shortages driven by manufacturing disruptions in China, and any major shock to supply routes can impact the entire industry.

The emerging-market advantage and risk

Viatris has disproportionate exposure to emerging markets compared with many rivals. This is both an asset and a liability. On the asset side: those regions have growing populations, expanding healthcare budgets, and enormous unmet demand for affordable medications. A company with distribution, manufacturing, and regulatory relationships across India, Brazil, Mexico, and other key markets can capture that growth.

On the liability side: those markets are more volatile. Currency fluctuations can wipe out margins overnight. Political instability, price controls, and import restrictions can hit revenue. Several emerging markets have periodically imposed price caps on generics or restricted imports, directly pressuring revenue. Viatris’s financial results often include foreign-exchange headwinds that can mask or exaggerate underlying business trends.

Pricing pressure and the generic economics

The fundamental economics of the generic business are brutal. A drug’s price in a market is set by three forces: the originator brand’s pricing, the number of competitors making the generic, and the buyer’s (insurers, hospitals, governments) willingness to pay. Once five or ten companies are selling the same generic, prices collapse to near the marginal cost of production. In some markets, the lowest-cost producer wins most of the volume; in others, buyers split purchases among multiple suppliers.

This means Viatris must constantly chase volume and cut costs to maintain profitability. The company does this through manufacturing efficiency, geographic diversification (selling the same drug in many countries at different prices), and continuous optimization of its product mix. But it also means there is a ceiling on growth rates and profitability in any mature generic market.

Biosimilars: the future, or another commodity trap?

Viatris is betting that biosimilars will offer better economics than traditional generics. Biosimilar drugs cost more to develop and require regulatory proof of “similarity” to the originator biologic, creating a higher bar than traditional generics. This means fewer competitors and, in theory, higher prices and margins.

But that advantage erodes once multiple biosimilar makers have approval. A popular originator biologic might eventually face three, four, or more biosimilar competitors, and prices fall. Viatris’s success depends on being first or second to market with key biosimilars, building customer relationships, and achieving scale before the field becomes saturated. Early indications suggest the company has executed reasonably well, but this is a newer business and results remain to be proven.

The pressures and uncertainties

Generic drug makers face structural headwinds. Rising raw-material costs in India and China can squeeze margins if they cannot be passed to buyers. Increased regulatory scrutiny around manufacturing quality, particularly in India, can force costly upgrades. Biosimilar markets may not develop as quickly or at the prices Viatris hopes. And consolidation among the buyers of drugs — health insurers, pharmacy benefit managers, hospital groups — gives those customers more leverage to demand lower prices.

For investors, Viatris is a high-volume, low-margin, cash-generative business in a mature market. The company does not invent new drugs; it manufactures and distributes existing ones at lower cost. That is a valuable business, but it requires operational excellence and does not typically support rapid growth.